Pangea Biomed Named to Fast Company’s Fourth Annual List of the Next Big Things in Tech

Pangea Biomed, the startup behind the advanced cancer intelligence AI platform ENLIGHT, today announced that it has been named to Fast Company’s fourth annual Next Big Things in Tech list, honoring emerging technology that has a profound impact for industries.

This year, 138 technologies developed by established companies, startups, or research teams are featured for their potential to revolutionize the lives of consumers, businesses, and society overall. Each featured technology is reaching key milestones to have a proven impact in the next five years.

Pangea Biomed developed ENLIGHT to democratize precision oncology. Current genomic-matching technology provides actionable insights to less than 15% of the patients coping with advanced cancer. “ENLIGHT, which uses both RNA-sequencing and AI analysis of digital pathology images, can bring that number up to over 80%, dramatically increasing the patient population that can benefit from effective modern drugs”, says Tuvik Beker, CEO of Pangea Biomed. Notably, the ENLIGHT-DP digital pathology solution, which was recently published in Nature Cancer, can be used in cases where Next-Generation Sequencing is not an option due to lack of time, lack of sufficient tissue material, or financial limitations.

“The Next Big Things in Tech provides a fascinating glimpse at near- and long-term technological breakthroughs across a variety of sectors,” says Brendan Vaughan, editor-in-chief of Fast Company. “Spanning everything from semiconductors to agricultural gene editing, the companies featured in this year’s list are tackling some of the world’s most pressing and vexing problems.”

Click here to see the final list.

About Fast Company

Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. The editor-in-chief is Brendan Vaughan. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication, Inc., and can be found online at fastcompany.com.

About Pangea Biomed

Founded in 2018, Pangea Biomed developed ENLIGHT – the world’s most advanced multi-cancer, multi-therapy response prediction platform. By combining machine learning and deep expression analysis, the company is mapping tumor molecular signatures to dynamically and adaptively personalize cancer care for a healthier world. Pangea aims to bring effective precision oncology to cancer patients, improve oncology drug development and empower oncologists to treat patients with success. Pangea is backed by NFX, and its technology has been published in leading journals, including Nature Cancer, Cell, Med, Science Advances, Cancer Cell, Journal for ImmunoTherapy of Cancer and Nature Communications.

Contact Information

Pangea Media

Media Relations

Pangea Biomed

media@pangeabiomed.com